Clinical TrialMay 26, 2026, 08:32 AM
PRF Technologies PRF-110 Shows Positive Preclinical Results
AI Summary
PRF Technologies Ltd. announced positive results from a head-to-head preclinical study comparing its lead product candidate, PRF-110, to ZYNRELEF for post-operative pain management. The study showed PRF-110 achieved sustained analgesic activity comparable to the approved benchmark over a 72-hour period. Importantly, PRF-110 is a ropivacaine-only, NSAID-free formulation, which the company believes offers a differentiated clinical profile due to ropivacaine's lower cardiac toxicity compared to bupivacaine.
Key Highlights
- PRF-110 demonstrated sustained analgesic activity comparable to ZYNRELEF over a 72-hour post-surgical period.
- PRF-110 is a ropivacaine-only, NSAID-free formulation, differentiating it from ZYNRELEF.
- Ropivacaine, the active ingredient in PRF-110, has shown lower cardiac toxicity than bupivacaine.
- The preclinical study was conducted in a validated pig incisional pain model.
- PRF-110's safety and local tolerability profile in pigs was consistent with prior preclinical experience.
- The findings provide supportive data for PRF-110's development and regulatory strategy.
Price Impact
More from PRFX